Read the full article on BostonGlobe.com ANDRIS NELSONS, the young new conductor of the Boston Symphony Orchestra, recently performed at the Tanglewood Gala Opening concerts. Listening to the exquisite performances, I was struck by the number of physicians and scientists…
Industry Musings
Next GenDrugs
by Yvonne Greenstreet, SVP, Pfizer Specialty Care •
Looking at the long-term horizon, the innovative medicines and vaccines of tomorrow will likely come from a broad spectrum of sources and geographies, enabled by collaborations, alliances and partnerships. No one entity working in isolation will be sufficient to achieve…
Industry Musings
On Financing Innovation
by William Heiden, CEO, AMAG Pharmaceuticals •
Financing innovation in our industry has historically been pursued through angel investors and venture capitalists. They provide the seed capital for a project or company so it can get to an early binary event, with additional infusions of capital needed…
Industry Musings
Boston’s biotech, pharma success will breed more success
by Christoph Westphal •
Read the full article published on bostonglobe.com BOSTON HAS benefited from an unexpected positive development in the last decade. Where we used to be simply the Hub of Biotech, we have suddenly turned into the Hub of the (Big) Pharma Universe.…
Industry Musings
Protecting Boston’s biotech status
by Christoph Westphal •
Read the full article on bostonglobe.com EAT LUNCH at Legal Seafood in Kendall Square any weekday, and you are likely to be surrounded by biomedical scientists from academia and biopharmaceutical companies. You might find the occasional information technology worker, but they…
Industry Musings
Hepatitis C cure may be costly — but also cost effective
by Christoph Westphal •
Read the full article on bostonglobe.com WHEN WAS the last time you heard of a genuine cure for a lethal disease? Hepatitis C has just been transformed from a chronic, and often fatal, condition to a disorder that can be…
Industry Musings
Boston’s blooming biotech ecosystem
by Christoph Westphal •
Read the full article on bostonglobe.com ONLY A few years ago, very few investors were interested in biotech. How quickly things change. Last year was the most active for biotechnology IPOs since 2000, with 38 biotech companies selling themselves on Wall…
Industry Musings
Focusing On Fundamentals
by David Sable, MD, Special Situations Life Sciences Fund •
The biotechnology and life sciences industries are built on a foundation of rapid and dramatic innovation in the basic sciences, an environment that can lead to well intentioned investing with poor outcomes. Part of the challenge is that companies in…